콘텐츠로 건너뛰기
Merck

CR0003L200

Mobius® 3 L Bioreactor

조직 및 계약 가격을 보려면 로그인를 클릭합니다.

크기 선택

보기 변경

제품정보 (DICE 배송 시 비용 별도)

eCl@ss:
32031690
UNSPSC Code:
23151806
기술 서비스
도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.
도움 문의


Quality Level

General description

The Mobius® 3 L bioreactor is a single-use,stirred tank bioreactor for bench-scale cell culture in fed-batch or perfusionmode. Its rigid design includes asemi-hemispherical shaped polycarbonate vessel, a multi-port high-densitypolyethylene (HDPE) headplate, a scoping marine impeller, both open pipe andsintered spargers, weldable C-Flex® tubing, and all necessary gas inlet andoutlet filters. It contains ports below the minimum working volume levelincluding one luer actuated sample port, one liquid inlet/outlet port, twoliquid addition lines, sparging lines and a harvest line. All gas and liquidaddition ports located below the minimum working volume incorporate checkvalves to ensure uni-directional flow of gas or liquid. The Mobius® 3 LBioreactor is pre-assembled, gamma irradiated and shipped ready to use.

Legal Information

C-Flex is a registered trademark of Saint-Gobain Performance Plastics Corp.
MOBIUS is a registered trademark of Merck KGaA, Darmstadt, Germany




시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문


문서

High cell density cryopreservation (HCDC) is a closed processing alternative to the traditional seed train expansion process. Learn more about the benefits of HCDC.

This page describes the financial and operational advantages offered by the Cellicon® Cell Retention Device in an N-1 perfusion process at the 2,000 L scale in comparison to a cell retention device from another supplier.

This page describes the design attributes of the Cellicon® filter assembly for cell retention and how they simplify scale-up of intensified upstream processes.

모든 기사 보기

관련 콘텐츠

Biopharmaceutical developers need efficient, productive upstream processes that deliver high quality monoclonal antibodies (mAbs) and other types of recombinant proteins. Process intensification can future-proof their manufacturing strategies, reduce costs, and increase facility flexibility.

Biopharmaceutical developers need efficient, productive upstream processes that deliver high quality monoclonal antibodies (mAbs) and other types of recombinant proteins. Process intensification can future-proof their manufacturing strategies, reduce costs, and increase facility flexibility.

This technical article breaks down the adenovirus vaccine manufacturing process and provides a case study on developing an accelerated and cost-effective single-use adenoviral vector vaccine.